%PDF-1.4
%
59 0 obj
<>
endobj
56 0 obj
<>
endobj
120 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-10T11:43:07Z
2024-03-29T03:47:22-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T03:47:22-07:00
application/pdf
Heather
2004-273.feb
uuid:e9a49526-1dd1-11b2-0a00-4c09277d8900
uuid:e9a49529-1dd1-11b2-0a00-d30000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
16 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
19 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
150 0 obj
[154 0 R]
endobj
151 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
8 0 0 8 545.468 56.4344 Tm
(347)Tj
ET
0 0 0 0 k
53.532 70.41 293 -16.998 re
f*
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.1462 Tm
[(Sacks, et al: V)110.7 (alidation of a surveillance case definition for arthritis)]TJ
/T1_1 1 Tf
2.4835 85.006 Td
[(costs. )54.8 (Arthritis Rheum 1993;36:439-46.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Centers for Disease Control and Prevention. Projected prevalence)]TJ
1.675 -1.25 Td
(of self-reported arthritis or chronic joint symptoms among persons)Tj
0 -1.25 TD
[(aged 65 years \321 United States, 2005-2030. Morb Mortal )17.7 (W)79.9 (eekly)]TJ
0 Tc T*
(Rep 2003;52:489-91.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(8.)-875.1 (Y)99.8 (elin E, Cisternas MG, Pasta DJ, )17.7 (T)35 (rupin L, Murphy L, Helmick)]TJ
1.675 -1.25 Td
(CG. Medical care expenditures and earning losses of persons with)Tj
T*
(arthritis and other rheumatic conditions in 1997: total and)Tj
T*
[(incremental estimates. )54.8 (Arthritis Rheum 2004;50:2317-26.)]TJ
-1.675 -1.25 Td
[(9.)-875.1 (Bellamy N, Bradley LA. )17.7 (W)79.9 (orkshop on chronic pain, pain control)]TJ
1.675 -1.25 Td
(and patient outcomes in rheumatoid arthritis and osteoarthritis.)Tj
T*
(Arthritis Rheum 1996;39:357-62.)Tj
-2.175 -1.25 Td
[(10.)-875.1 (Katz JN. Preferences, quality)64.8 (, and the \(under\)utilization of total)]TJ
2.175 -1.25 Td
[(joint arthroplasty)64.8 (. Med Care 2001;39:203-5.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Hootman JM, Helmick CG, Schappert SM. Magnitude and )]TJ
2.1381 -1.25 Td
(characteristics of arthritis and other rheumatic conditions on )Tj
T*
[(ambulatory medical care visits, United States, 1997. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2002;47:571-81.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Meenan RF)79.7 (, Callahan LF)79.7 (, Helmick CG. )17.7 (The National )54.8 (Arthritis)]TJ
2.175 -1.25 Td
[(Action Plan: )54.8 (A)-220.1 (public health strategy for a looming epidemic.)]TJ
T*
(Arthritis Care Res 1999;12:79-81.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Helmick CG, Lawrence RC, Pollard RA, Lloyd E, Heyse SP)110.7 (.)]TJ
2.175 -1.25 Td
[(Arthritis and other rheumatic conditions: who is af)17.7 (fected now)64.8 (. )17.7 (Who)]TJ
T*
[(will be af)17.7 (fected later)54.8 (. )54.7 (Arthritis Care Res 1995;8:203-1)36.8 (1.)]TJ
30.825 28.75 Td
[(14.)-875.1 (Rao JK, Callahan LF)79.7 (, Helmick CG. Characteristics of persons with)]TJ
2.175 -1.25 Td
(self-reported arthritis and other rheumatic conditions who do not)Tj
T*
[(see a doctor)54.8 (. J Rheumatol 1997;24:169-73.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Pincus )17.7 (T)74 (, Swearington C, )17.7 (W)79.9 (olfe F)79.7 (.)-0.1 ( )17.7 (T)69.9 (oward a Multidimensional)]TJ
2.175 -1.25 Td
[(Health )54.8 (Assessment Questionnaire \(MDHAQ\). )54.8 (Assessment of)]TJ
T*
(advanced activities of daily life and psychological status in the)Tj
T*
[(patient-friendly Health )54.8 (Assessment Questionnaire format. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 1999;42:2220-30.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(16.)-875.1 (Ramsey DR, Raynauld J, Fries JF)79.7 (. )17.7 (The Health )54.8 (Assessment)]TJ
2.175 -1.25 Td
[(Questionnaire 1992: status and review)64.8 (. )54.8 (Arthritis Care Res)]TJ
0 Tc 0 Tw T*
[(1992;5:1)36.9 (19-29.)]TJ
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Sackett DL, Haynes RB, Guyatt GH, )17.7 (T)35 (ugwell P)110.7 (, editors. Clinical)]TJ
2.175 -1.25 Td
(epidemiology: a basic science for clinical medicine. 2nd ed.)Tj
T*
(Boston: Little, Brown and Company; 1991:25-31.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Mili F)79.7 (, Helmick CG, Zack MM, Moriarty DG. Health related )]TJ
2.175 -1.25 Td
(quality of life among adults reporting arthritis: analysis of data)Tj
T*
(from the Behavioral Risk Factor Surveillance System, US, 1996-99.)Tj
T*
(J Rheumatol 2003;30:160-6.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (LaV)110.7 (alley M, McAlindon )17.7 (TE, Evans S, Chaisson CE, Felson DT)73.9 (.)]TJ
2.175 -1.25 Td
(Problems in the development and validation of questionnaire-based)Tj
T*
(screening instruments for ascertaining cases with symptomatic knee)Tj
T*
[(osteoarthritis. )17.7 (The Framingham Study)64.8 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
[(2001;44:1)36.9 (105-13.)]TJ
ET
0 0 0 0 k
/GS0 gs
104.631 81.583 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 81.583 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>stream
8;Z\5d1X;M#ikr7OP`o:6>0$$3H%)0nP4;'"e(+E>50hn#6'Y!(?h?]n$grZuYDjS_"u8C$Tt/>!(`j:u@Z$$L]`3U)nDo3ua:r.+nTSR*jD+
[Jg[$5gr.WS2IUu>gg$t".u=W.VP,Cq&"V%$uW=qT0Pc(^e.$+\mJ$m4Tt^;3N;1Y
Xak66)cZ[:g"Fqeoe?mN9pj!pP0%_M2='TR*-f4u(6#e[M]9m[!,=(<'24?=,qcIT
GW:4]cQR_/+cJ#>5B,!\XG!5,S2=bC>?$ZTcD`t<^llN;0+@Yg7h"0s%bo8+.D!oM
=,*0V,=j6N_tfPbYoQ0B9*FiNBB$Q9YqpS[.kYRk61mHYYft+J1qWk:4su.:'FKO\
Thm-O$ACg?n9r@]/
endstream
endobj
43 0 obj
[/Indexed/DeviceRGB 255 42 0 R]
endobj
42 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
62 0 obj
<>
endobj
71 0 obj
<>
endobj
103 0 obj
<>
endobj
125 0 obj
<>
endobj
70 0 obj
<>
endobj
96 0 obj
<>stream
H|TPWQq{B ~ `@ EAPaQϊA' (HD#`P?ѸfwF4Eljwv+Uzu=cFpߨQjcݟqY,#%8c]&ƜD\Q/iHIG^LY%;#q\tq2&%^#"A>;Vxт9 XU7h1Z0uFHPϓݢX<^UUZBW(5XuBF)w[.WĆWUb☻a*ScX`F8Hl9l&?&"xqs2 焓MVMj `-줶
ߝnfg'/ԓض+s]Դ7AJem!Mcjz ForDZ!s-~%a.\g uT0s,PA(߸uLTbAeL$D~rӛGߌ?Ee}*N593ѫwyNC6*Hc {dETMNJdAF yP]wڞ;'K
32ElZi/5] PL0e%(HĂԙ7mȓ;pAðrvw* rC#f.+rD)*S
՞-몪ʮ^~jo}DNjz*"_[]]zx~WX(wIEe/77eTdTiGVԝQ$&&$$ ?ۖw^|A5O+-%'АѐY֔U}QIʼn5u"1A @'4A 4HY\\?FVRݑ[Tæ~r 8~F(@ !fcTVSij7kjebW
{80
Io*zHuuf'u
\30~ހl ,P7ճ06/{dnBAȊ畎B=*8-e?B´47*D>NxdS+-jn[$YE䚰/3O~~2l0"0elpv[%CKXGnUޖ^QlH4U[jeI]V,D2IwnO2CWSG5z$9^>6Q|}p D PWuW4v=iB&h}N\]Xݣ`I1,@8ڗYu(3`?r.`ؤTu,x8lla~9ĺq'Dp`|ǗPqY92lњ1+0# Kd+y2hcaAPWK=ma\cRf59]J
>cնwPЖ/AXW3.58y77IF!z¢?24pS?oz47)I͖;]oVR6!_>G/+ =N=oWwl[*/'V@F;'Bs/jz%LLZއqEb
|̠OB4+][/t>Qvp+^O}#8 ܬxnAt&;E{=c ?4`y`}Gg&Ӟ;UkjvF5ueaCDKq*\IZi]8EQq* "xJ
\# <ttu]ڥuu83'a\IJww7%qV摫
!4WJj;/8B!w8
pPӫ碢*i=Hˣ{}I,uX@x˾yuMm-'/j$$hi`qME.)*Di0ӨjKҬ9Gc8M_i>x\q^)..Zmk[EO0ȰN*LC=`*